You are here
Novavax delays US trial start of Covid-19 vaccine to November
[NEW YORK] Novavax on Tuesday delayed the timeline for beginning a late-stage US trial of its experimental coronavirus vaccine by roughly one month.
The company said it would begin the trial by the end of November. It previously expected to start this month.
Novavax said it also expects interim data from an ongoing late-stage UK trial of its coronavirus vaccine in the first quarter of next year.
The company said it had expanded its enrollment target in the UK trial to 15,000 volunteers from 10,000. It expects this could help assess safety and effectiveness of the vaccine in a shorter time period.